Clinicopathologic Analysis of Pituitary Adenoma: A Single Institute Experience.
10.3346/jkms.2014.29.3.405
- Author:
Hwa Jin CHO
1
;
Hanna KIM
;
Yoon Jin KWAK
;
Jeong Wook SEO
;
Sun Ha PAEK
;
Chul Ho SOHN
;
Jung Min YUN
;
Da Seu Ran KIM
;
Peter KANG
;
Peom PARK
;
Sung Hye PARK
Author Information
1. Department of Pathology, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea. shparknp@snu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Pituitary Gland;
Pituitary Neoplasms;
Pituitary Adenoma;
Clinicopathological Study;
Pituitary Hormone
- MeSH:
Adenoma/*pathology;
Adolescent;
Adult;
Age Factors;
Aged;
Aged, 80 and over;
Central Nervous System Cysts/pathology;
Child;
Female;
Growth Hormone/metabolism;
Humans;
Immunohistochemistry;
Male;
Middle Aged;
Pituitary Neoplasms/*pathology;
Prolactin/metabolism;
Recurrence;
Sex Factors;
Young Adult
- From:Journal of Korean Medical Science
2014;29(3):405-410
- CountryRepublic of Korea
- Language:English
-
Abstract:
Pituitary adenoma (PA) is a common benign neuroendocrine tumor; however, the incidence and proportion of hormone-producing PAs in Korean patients remain unknown. Authors analyzed 506 surgically resected and pathologically proven pituitary lesions of the Seoul National University Hospital from 2006 to 2011. The lesions were categorized as: PAs (n = 422, 83.4%), Rathke's cleft cysts (RCCs) (n = 54, 10.6%), inflammatory lesions (n = 8, 1.6%), meningiomas (n = 4), craniopharyngiomas (n = 4), granular cell tumors (n = 1), metastatic renal cell carcinomas (n = 2), germinomas (n = 1), ependymomas (n = 1), and unsatisfactory specimens (n = 9, 1.8%). PAs were slightly more prevalent in women (M: F = 1:1.17) with a mean age of 48.8 yr (9-80 yr). Immunohistochemical analysis revealed that prolactin-producing PAs (16.6%) and growth hormone-producing adenomas (9.2%) were the most common functional PAs. Plurihormonal PAs and nonfunctioning (null cell) adenomas were found in 14.9% and 42.4% of patients with PAs, respectively. The recurrence rate of PAs was 11.1%, but nearly 0% for the remaining benign lesions such as RCCs. 25.4% of patients with PAs were treated by gamma-knife after surgery due to residual tumors or regrowth of residual tumor. In conclusion, the pituitary lesions and the proportions of hormone-producing PAs in Korean patients are similar to those of previous reports except nonfunctioning (null cell) PAs, which are unusually frequent.
